| Yao-Shih Hsu, Rong-Nan Chieh, Chau-Ting Yeh, I-Shyan Sheen, Hung-Yi Chiou, Chia-Ming Chu, and Tun-Fan Liaw |
------>authors3_c= ------>paper_class1=1 ------>Impact_Factor=10.416 ------>paper_class3=2 ------>paper_class2=1 ------>vol=35 ------>confirm_bywho=hychiou ------>insert_bywho=hychiou ------>Jurnal_Rank=4.3 ------>authors4_c= ------>comm_author= ------>patent_EDate=None ------>authors5_c= ------>publish_day=1 ------>paper_class2Letter=None ------>page2=1527 ------>medlineContent= ------>unit=J0200 ------>insert_date=20020710 ------>iam=5 ------>update_date= ------>author=??? ------>change_event=4 ------>ISSN= ------>authors_c= ------>score=487 ------>journal_name=Hepatology ------>paper_name=Long-Term Outcome After Spontaneous HBeAg Seroconversion In Patient With Chronic Hepatitis B ------>confirm_date=20060419 ------>tch_id=079002 ------>pmid=12029639 ------>page1=1522 ------>fullAbstract=During the course of chronic hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) seroconversion to its antibody (anti-HBe) often coincides with normalization of liver biochemical test and clinical remission, but data regarding long-term outcome after spontaneous seroconversion are still scarce. Excluding patients with other virus(es) concurrent infection, 283 patients with chronic HBV infection were followed up for at least 1 year after spontaneous HBeAg seroconversion to anti-HBe. Follow-up studies included clinical, biochemical, and virologic evaluation and hepatocellular carcinoma (HCC) screening with ultrasonography and alpha-fetoprotein assay. During a median follow-up period of 8.6 years (range, 1 to 18.4 years) after HBeAg seroconversion in 283 patients, 189 (66.8%) showed sustained remission, whereas the remaining 94 (33.2%) experienced alanine aminotransferase (ALT) elevation over twice the upper limit of normal: 12 (4.2%) associated with HBeAg reversion, 68 (24%) with detectable serum HBV DNA but HBeAg negative, and 14 (4.9%) of undetermined causes. Of the 269 patients without evidence of cirrhosis at the time of HBeAg seroconversion, 21 (7.8%) developed cirrhosis with a cumulative incidence and relative risk significantly higher in patients developing active hepatitis than in patients with sustained remission (P <.05). HCC developed in 6 (2.2%) of the 283 patients, also with a significantly higher cumulative incidence in patients developing active hepatitis after HBeAg seroconversion (P <.005). In conclusion, the results suggest that spontaneous HBeAg seroconversion confers favorable long-term outcomes. However, active hepatitis still may develop and lead to cirrhosis and HCC. ------>tmu_sno=None ------>sno=5686 ------>authors2= ------>authors3= ------>authors4= ------>authors5= ------>authors6= ------>authors6_c= ------>authors=Yao-Shih Hsu, Rong-Nan Chieh, Chau-Ting Yeh, I-Shyan Sheen, Hung-Yi Chiou, Chia-Ming Chu, and Tun-Fan Liaw ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c= ------>publish_area=0 ------>updateTitle=Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. ------>language=2 ------>check_flag= ------>submit_date= ------>country=None ------>no=6 ------>patent_SDate=None ------>update_bywho= ------>publish_year=2002 ------>submit_flag= ------>publish_month=1 |